Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CNSP | 8-K | neutral | 3/10 | CNS Pharmaceuticals filed an 8-K posting an investor presentation detailing its strategic pivot after a $22.5M PIPE fina | Jul 3, 2026 |
| CRIS | 8-K | neutral | 3/10 | Curis Inc. filed a certificate of amendment to effect a 1-for-20 reverse stock split of its common stock, effective July | Jul 3, 2026 |
| BRNS | 8-K | bearish | 6/10 | Barinthus Biotherapeutics received a 180-day extension from Nasdaq, until December 28, 2026, to regain compliance with t | Jul 3, 2026 |
| RNAZ | 8-K | neutral | 3/10 | TransCode Therapeutics adjourned its 2026 Annual Meeting to July 20, 2026, pending Nasdaq's review of its initial listin | Jul 3, 2026 |
| VERU | 8-K, 424B5 | bearish | 6/10 | Veru Inc. entered into an at-the-market (ATM) equity Sales Agreement with Oppenheimer and Canaccord Genuity to sell up t | Jul 3, 2026 |
| ABVX | 424B5 | bearish | 6/10 | Abivax is raising approximately $759.8 million in net proceeds through a public offering of 6,400,000 ADSs at $125.00 pe | Jul 3, 2026 |
| ABVX | 6-K | bearish | 6/10 | Abivax SA filed a 6-K on July 2, 2026, disclosing the entry into an underwriting agreement for a public offering of 6,40 | Jul 3, 2026 |
| RKDA | 8-K | neutral | 2/10 | On July 1, 2026, Arcadia Biosciences' Board and Compensation Committee approved a discretionary cash bonus of $169,000 t | Jul 3, 2026 |
| NGEN | 6-K | bearish | 5/10 | NervGen Pharma Corp. entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market (ATM) equity | Jul 3, 2026 |
| SUPN | COURT-RULING | neutral | 2/10 | Supernus won a discovery dispute in its consolidated Hatch-Waxman patent litigation defending Qelbree® (viloxazine) agai | Jul 3, 2026 |
| VTRS | COURT-RULING | neutral | 2/10 | The District of New Jersey denied plaintiff's motion to vacate the prior dismissal of a product liability/consumer fraud | Jul 3, 2026 |
| XERS | CLUSTER | neutral | 4/10 | Two XERS insiders (Kevin McCulloch and Beth Hecht) sold a combined $856K in open-market sales on July 1, 2026, represent | Jul 3, 2026 |
| CTNM | CLUSTER | neutral | 3/10 | Three top insiders (CEO, CSO, and CMO) at Contineum Therapeutics exercised and sold shares in a coordinated cluster tota | Jul 3, 2026 |
| RPRX | CLUSTER | neutral | 2/10 | Two EVP-level insiders at Royalty Pharma (RPRX) sold a combined $7.85M in shares over a 7-day window, but this represent | Jul 3, 2026 |
| VTRS | COURT-RULING | bullish | 4/10 | The District Court of New Jersey denied plaintiff Norton's motion to vacate the dismissal of her product-liability lawsu | Jul 3, 2026 |
| MAZE | CLUSTER | neutral | 3/10 | CEO Jason Coloma sold ~$1.03M and CSBO Atul Dandekar sold $210K in open-market transactions over a 7-day window, totalin | Jul 3, 2026 |
| JNJ | COURT-RULING | neutral | 1/10 | The District Court of New Jersey granted plaintiff Monica Jackson's motion for voluntary dismissal without prejudice of | Jul 3, 2026 |
| KYMR | CLUSTER | bearish | 5/10 | Three Kymera insiders, including CEO Nello Mainolfi, CFO Bruce Jacobs, and a director, sold a combined ~$13.2M in open-m | Jul 3, 2026 |
| QURE | CLUSTER | bearish | 4/10 | Cluster of insider sales at uniQure following two recent $225M and $150M capital raises, with total open-market insider | Jul 3, 2026 |
| SION | CLUSTER | neutral | 4/10 | Two Sionna Therapeutics directors (OrbiMed Advisors LLC and Peter A. Thompson) each sold 115,844 shares at $45.50 on Jun | Jul 3, 2026 |
| MRK | COURT-RULING | bullish | 5/10 | In the Zostavax MDL pending in the Eastern District of Pennsylvania, Judge Bartle granted Merck's motion to dismiss with | Jul 3, 2026 |
| HALO | CLUSTER | neutral | 3/10 | Two HALO directors sold a combined $624K in open-market sales over a 3-day window, with the bulk ($548K) from Director K | Jul 3, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP/GC Paul Mahon executed a cluster of open-market sales on July 2, 2026, totaling approximat | Jul 3, 2026 |
| VTRS | COURT-RULING | mixed | 6/10 | The District Court of New Jersey adopted a Special Master's recommendation to partially grant Teva's motion to dismiss M | Jul 3, 2026 |
| TEVA | COURT-RULING | bullish | 6/10 | The District Court of New Jersey adopted a Special Master's Report and Recommendation, partially granting Teva's motion | Jul 3, 2026 |
| TEVA | COURT-RULING | neutral | 5/10 | The District of New Jersey adopted a Special Master's recommendation to partially dismiss Mylan's antitrust lawsuit agai | Jul 2, 2026 |
| VTRS | COURT-RULING | bearish | 5/10 | The district court partially granted Teva's motion to dismiss Mylan's antitrust complaint, dismissing with prejudice all | Jul 2, 2026 |
| IQV | COURT-RULING | neutral | 1/10 | A federal district court granted summary judgment against IQVIA on a single-plaintiff TCPA claim over four unsolicited f | Jul 2, 2026 |
| SYRE | CLUSTER | neutral | 3/10 | A small insider selling cluster at Spyre Therapeutics (SYRE) saw CEO Turtle Cameron and CFO Scott Burrows sell a combine | Jul 2, 2026 |
| NVO | COURT-RULING | neutral | 2/10 | The Judicial Panel on Multidistrict Litigation issued a Conditional Transfer Order adding the product liability case Pri | Jul 2, 2026 |